Eugenol-loaded mesoporous silica nanoparticles enhance the sensitivity of cisplatin against AGS human gastric adenocarcinoma cell line
Source abstract
Abstract
Gastric cancer is one of the most common cancers with a high mortality rate worldwide. Eugenol possesses antioxidant, anti-inflammatory, antimicrobial, and anticancer properties. Mesoporous silica nanoparticles (MSN) have been promising carriers for drug delivery. This study aimed to investigate the synergism effect of free eugenol/eugenol-MSN and cisplatin on the AGS human gastric adenocarcinoma cell line. In this study, MSN was synthesized and loaded with eugenol. Cultured AGS cells were treated with different concentrations of free eugenol/eugenol-MSN individually and in combination with cisplatin. MTT assay, scratch assay, and flow cytometry were employed to assess cell viability, migration, and apoptosis. The antioxidant properties of free eugenol/eugenol-MSN and their effect on superoxide dismutase (SOD) activity were evaluated. Real-time PCR was used to study the effect of free eugenol/eugenol-MSN on the expression of metastatic pathway genes such as MMP2, MMP9, and KRAS, and some genes involved in apoptosis including caspase 3, caspase 8, and caspase 9. A synergism effect of free eugenol/eugenol-MSN and cisplatin (CI < 1) was observed. Combination therapies were significantly more effective in cell growth reduction, migration inhibition, and apoptosis induction than single treatments. Free eugenol has more potential in DPPH radical scavenging, and eugenol-MSN has more potential in increasing SOD activity. The relative expression of caspase 3, caspase 8, and caspase 9 genes in the treated cells increased compared to the control group, and the expression of MMP2, MMP9, and KRAS oncogenes decreased significantly. Eugenol loading in MSN leads to increasing the sensitivity of cisplatin against gastric cancer.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Mesoporous Materials and Catalysis · Metal complexes synthesis and properties · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (58)
Show source-provided references
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–42410.3322/caac.21492 ↗
2. Joshi SS, Badgwell BD (2021) Current treatment and recent progress in gastric cancer. CA Cancer J Clin 71:264–27910.3322/caac.21657 ↗
3. Martinho N, Santos TC, Florindo HF, Silva LC (2019) Cisplatin-membrane interactions and their influence on platinum complexes activity and toxicity. Front Physiol 9:189810.3389/fphys.2018.01898 ↗
4. Hannon MJ (2007) Metal-based anticancer drugs: from a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. Pure Appl Chem 79:2243–226110.1351/pac200779122243 ↗
5. Stewart DJ (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63:12–3110.1016/j.critrevonc.2007.02.001 ↗
6. Khalil AA, ur Rahman U, Khan MR, Sahar A, Mehmood T, Khan M (2017) Essential oil eugenol: sources, extraction techniques and nutraceutical perspectives. RSC Adv 7:32669-3268110.1039/C7RA04803C ↗
7. Mak K-K, Kamal M, Ayuba S, Sakirolla R, Kang Y-B, Mohandas K et al (2019) A comprehensive review on eugenol’s antimicrobial properties and industry applications: a transformation from ethnomedicine to industry. Pharmacogn Rev 13:1–910.4103/phrev.phrev_46_18 ↗
8. Marchese A, Barbieri R, Coppo E, Orhan IE, Daglia M, Nabavi SF et al (2017) Antimicrobial activity of eugenol and essential oils containing eugenol: a mechanistic viewpoint. Crit Rev Microbiol 43:668–68910.1080/1040841X.2017.1295225 ↗
9. Barboza JN, da Silva Maia BFC, Silva RO, Medeiros JVR, de Sousa DP (2018) An overview on the anti-inflammatory potential and antioxidant profile of eugenol. Oxid Med Cell Longev 2018:1–910.1155/2018/3957262 ↗
10. Nisar MF, Khadim M, Rafiq M, Chen J, Yang Y, Wan CC (2021) Pharmacological properties and health benefits of eugenol: a comprehensive review. Oxid Med Cell Longev 2021:1–1410.1155/2021/2497354 ↗
11. Abdullah ML, Hafez MM, Al-Hoshani A, Al-Shabanah O (2018) Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells. BMC Complement Altern Med 18:1–1110.1186/s12906-018-2392-5 ↗
12. Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G et al (2007) Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer 6:1–1210.1186/1476-4598-6-8 ↗
13. Hussain A, Brahmbhatt K, Priyani A, Ahmed M, Rizvi TA, Sharma C (2011) Eugenol enhances the chemotherapeutic potential of gemcitabine and induces anticarcinogenic and anti-inflammatory activity in human cervical cancer cells. Cancer Biother Radiopharm 26:519–527
14. Islam SS, Al-Sharif I, Sultan A, Al-Mazrou A, Remmal A, Aboussekhra A (2018) Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway. Mol Carcinog 57:333–34610.1002/mc.22758 ↗
15. Yi J-L, Shi S, Shen Y-L, Wang L, Chen H-Y, Zhu J et al (2015) Myricetin and methyl eugenol combination enhances the anticancer activity, cell cycle arrest and apoptosis induction of cis-platin against HeLa cervical cancer cell lines. Int J Clin Exp Pathol 8:1116
16. Fangjun L, Zhijia Y (2018) Tumor suppressive roles of eugenol in human lung cancer cells. Thorac Cancer 9:25–2910.1111/1759-7714.12508 ↗
17. Carrasco AH, Espinoza CL, Cardile V, Gallardo C, Cardona W, Lombardo L et al (2008) Eugenol and its synthetic analogues inhibit cell growth of human cancer cells (Part I). J Braz Chem Soc 19:543–54810.1590/S0103-50532008000300024 ↗
18. de Sa Junior PL, Câmara DAD, Costa AS, Ruiz JLM, Levy D, Azevedo RA et al (2016) Apoptotic effect of eugenol envolves G2/M phase abrogation accompanied by mitochondrial damage and clastogenic effect on cancer cell in vitro. Phytomedicine 23:725–73510.1016/j.phymed.2016.03.014 ↗
19. Yoo C-B, Han K-T, Cho K-S, Ha J, Park H-J, Nam J-H et al (2005) Eugenol isolated from the essential oil of Eugenia caryophyllata induces a reactive oxygen species-mediated apoptosis in HL-60 human promyelocytic leukemia cells. Cancer Lett 225:41–5210.1016/j.canlet.2004.11.018 ↗
20. Jaganathan SK, Mazumdar A, Mondhe D, Mandal M (2011) Apoptotic effect of eugenol in human colon cancer cell lines. Cell Biol Int 35:607–61510.1042/CBI20100118 ↗
21. Tran S, DeGiovanni P-J, Piel B, Rai P (2017) Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med 6:1–2110.1186/s40169-017-0175-0 ↗
22. Haider M, Abdin SM, Kamal L, Orive G (2020) Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics 12:28810.3390/pharmaceutics12030288 ↗
23. Sarkar A, Ghosh S, Chowdhury S, Pandey B, Sil PC (2016) Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells. BiochimBiophys Acta (BBA) Gen Subj 1860:2065–207510.1016/j.bbagen.2016.07.001 ↗
24. Argyo C, Weiss V, Bräuchle C, Bein T (2014) Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery. Chem Mater 26:435–45110.1021/cm402592t ↗
25. Mai WX, Meng H (2013) Mesoporous silica nanoparticles: a multifunctional nano therapeutic system. Integr Biol 5:19–2810.1039/c2ib20137b ↗
26. Ma’Mani L, Nikzad S, Kheiri-Manjili H, Al-Musawi S, Saeedi M, Askarlou S et al (2014) Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy. Eur J Med Chem 83:646–65410.1016/j.ejmech.2014.06.069 ↗
27. Alyassin Y, Sayed EG, Mehta P, Ruparelia K, Arshad MS, Rasekh M et al (2020) Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents. Drug Discov Today 25:1513–152010.1016/j.drudis.2020.06.006 ↗
28. Fan J, Fang G, Wang X, Zeng F, Xiang Y, Wu S (2011) Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles. Nanotechnology 22:45510210.1088/0957-4484/22/45/455102 ↗
29. Brunauer S, Emmett PH, Teller E (1938) Adsorption of gases in multimolecular layers. J Am Chem Soc 60:309–31910.1021/ja01269a023 ↗
30. Chou T-C, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–5510.1016/0065-2571(84)90007-4 ↗
31. Fu J, Zhang N, Chou JH, Dong H-J, Lin S-F, Ulrich-Merzenich GS et al (2016) Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. Synergy 3:15–3010.1016/j.synres.2016.06.001 ↗
32. Seux M, Peuget S, Montero M, Siret C, Rigot V, Clerc P et al (2011) TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression. Oncogene 30:3049–306110.1038/onc.2011.25 ↗
33. Kedare SB, Singh R (2011) Genesis and development of DPPH method of antioxidant assay. J Food Sci Technol 48:412–42210.1007/s13197-011-0251-1 ↗
34. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 25:402–40810.1006/meth.2001.1262 ↗
35. Zagidullin B, Aldahdooh J, Zheng S, Wang W, Wang Y, Saad J et al (2019) DrugComb: an integrative cancer drug combination data portal. Nucleic Acids Res 47:W43–W5110.1093/nar/gkz337 ↗
36. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H (2012) Nanoparticles as drug delivery systems. Pharmacol Rep 64:1020–103710.1016/S1734-1140(12)70901-5 ↗
37. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–165910.1016/j.addr.2004.02.014 ↗
38. Gurunathan S, Kang M-H, Qasim M, Kim J-H (2018) Nanoparticle-mediated combination therapy: Two-in-one approach for cancer. Int J Mol Sci 19:326410.3390/ijms19103264 ↗
39. Jeong J-M, Choi C-H, Kang S-K, Lee I-H, Lee J-Y, Jung H (2007) Antioxidant and chemosensitizing effects of flavonoids with hydroxy and/or methoxy groups and structure-activity relationship. J Pharm Pharm Sci 10:537–54610.18433/J3KW2Z ↗
40. Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF (2019) An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol 71:1185–119810.1111/jphp.13098 ↗
41. Golombek SK, May J-N, Theek B, Appold L, Drude N, Kiessling F et al (2018) Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 130:17–3810.1016/j.addr.2018.07.007 ↗
42. Watermann A, Brieger J (2017) Mesoporous silica nanoparticles as drug delivery vehicles in cancer. Nanomaterials 7:18910.3390/nano7070189 ↗
43. Lungare S, Hallam K, Badhan RK (2016) Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery. Int J Pharm 513:280–29310.1016/j.ijpharm.2016.09.042 ↗
44. Nasr SS, Nasra M, Hazzah HA, Abdallah OY (2019) Mesoporous silica nanoparticles, a safe option for silymarin delivery: preparation, characterization, and in vivo evaluation. Drug Deliv Transl Res 9:968–97910.1007/s13346-019-00640-3 ↗
45. Freidus LG, Kumar P, Marimuthu T, Pradeep P, Choonara YE (2021) Theranostic Mesoporous Silica Nanoparticles Loaded With a Curcumin-Naphthoquinone Conjugate for Potential Cancer Intervention. Front Mol Biosci 8:67079210.3389/fmolb.2021.670792 ↗
46. Manikandan P, Vinothini G, VidyaPriyadarsini R, Prathiba D, Nagini S (2011) Eugenol inhibits cell proliferation via NF-κB suppression in a rat model of gastric carcinogenesis induced by MNNG. Investig New Drugs 29:110–11710.1007/s10637-009-9345-2 ↗
47. Manikandan P, Murugan RS, Priyadarsini RV, Vinothini G, Nagini S (2010) Eugenol induces apoptosis and inhibits invasion and angiogenesis in a rat model of gastric carcinogenesis induced by MNNG. Life Sci 86:936–94110.1016/j.lfs.2010.04.010 ↗
48. Sarkar A, Bhattacharjee S, Mandal DP (2015) Induction of apoptosis by eugenol and capsaicin in human gastric cancer AGS cells-elucidating the role of p53. Asian Pac J Cancer Prev 16:6753–675910.7314/APJCP.2015.16.15.6753 ↗
49. Vidhya N, Devaraj SN (2011) Induction of apoptosis by eugenol in human breast cancer cells. Indian J Exp Biol 49(11):871–8
50. Abdullah ML, Al-Shabanah O, Hassan ZK, Hafez MM (2021) Eugenol-induced autophagy and apoptosis in breast cancer cells via PI3K/AKT/FOXO3a pathway inhibition. Int J Mol Sci 22:924310.3390/ijms22179243 ↗
51. Permatasari HK, Effendi AB, Qhabibi FR, Fawwaz F, Dominique A (2021) Eugenol isolated from Syzygium aromaticum inhibits HeLa cancer cell migration by altering epithelial-mesenchymal transition protein regulators. J Appl Pharm Sci 11:049-053
52. Das A, Harshadha K, SK DK, Jayaprakash B (2018) Evaluation of therapeutic potential of eugenol-a natural derivative of Syzygiumaromaticum on cervical cancer. Asian Pac J Cancer Prev: APJCP 19:1977
53. Cui Z, Liu Z, Zeng J, Chen L, Wu Q, Mo J et al (2019) Eugenol inhibits non-small cell lung cancer by repressing expression of NF-κB-regulated TRIM59. Phytother Res 33:1562–156910.1002/ptr.6352 ↗
54. Kim G-C, Choi D-S, Lim J-S, Jeong H-C, Kim I-R, Lee M-H et al (2006) Caspases-dependent apoptosis in human melanoma cell by eugenol. Korean J Anat 39:245–253
55. Ghosh R, Nadiminty N, Fitzpatrick JE, Alworth WL, Slaga TJ, Kumar AP (2005) Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. J Biol Chem 280:5812–581910.1074/jbc.M411429200 ↗
56. Majeed H, Antoniou J, Fang Z (2014) Apoptotic effects of eugenol-loaded nanoemulsions in human colon and liver cancer cell lines. Asian Pac J Cancer Prev 15:9159–916410.7314/APJCP.2014.15.21.9159 ↗
57. Fathy M, Fawzy MA, Hintzsche H, Nikaido T, Dandekar T, Othman EM (2019) Eugenol exerts apoptotic effect and modulates the sensitivity of HeLa cells to cisplatin and radiation. Molecules 24:397910.3390/molecules24213979 ↗
58. Islam SS, Aboussekhra A (2019) Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway. J Exp Clin Cancer Res 38:1–1410.1186/s13046-019-1360-3 ↗